Kura Oncology (KURA)
(Real Time Quote from BATS)
$18.89 USD
-0.23 (-1.20%)
Updated Aug 9, 2024 02:28 PM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Kura Oncology, Inc. [KURA]
Reports for Purchase
Showing records 161 - 180 ( 263 total )
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; AML Expansion Cohorts Set to Initiate Mid-Year
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; KO-539 Program Expansion With Clear Focus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Additional Validation for Menin Inhibitors, but SNDX-5613 Profile Struggles
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; KO-539 Dose-Escalation Ongoing; BTD for Tipifarnib
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Nice Morning Feather in the Kura Cap; Keen Focus on KO-539; Target to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Early Targeting Win in Very Tough Group for KO-539; Target Upped to $45
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Early KOMET Data Validates Broad AML Development Plan
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Acute Myeloid Leukemia: Current Treatment and Therapies in Development
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Results; Anticipation Mounts for ASH; First Look Points in Right Direction for KO-539
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Programs Expanding with New Cohorts for KO-539 and Tipi Planned
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R